Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy

CONCLUSIONS: Pembrolizumab monotherapy achieved durable treatment responses. Patients with a high baseline T-cell clonality had prolonged disease control with pembrolizumab.PMID:38629963 | DOI:10.1158/1078-0432.CCR-23-2947

Source: Clinical Breast Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Toshiaki Iwase Evan N Cohen Hui Gao Angela Alexander Megumi Kai Vivian Chiv Xiaoping Wang Savitri Krishnamurthy Diane Liu Yu Shen Kumiko Kida Alexandre Reuben Rachel Layman David Ramirez Debu Tripathy Stacy L Moulder Clinton Yam Vicente Valero Bora Lim Ja Source Type: research